
First patient dosed in Seaport’s anxiety clinical trial
Biopharmaceutical company Seaport Therapeutics has announced that the first patient has been dosed in a Phase I clinical trial of its treatment for generalised anxiety disorder. Seaport’s GlyphAgo is an oral prodrug of agomelatine, which is a clinically validated melatonin receptor agonist and serotonin 2C receptor antagonist. Read More







